Linden LLC

Chesapeake IRB Announces Acquisition of Compass IRB

February 3, 2016 | For Immediate Release

Columbia, MD (February 2, 2016) – Chesapeake IRB (“Chesapeake”), the leading technology-enabled independent institutional review board (“IRB”) serving the clinical research industry, announced it has acquired Compass IRB (“Compass”), a central IRB located in Mesa, AZ.

The Compass IRB acquisition provides Chesapeake with additional AAHRPP accredited review capacity and a talented staff that broadens Chesapeake’s geographic presence.

“Compass shares our commitment to human subject protection, customer service, and regulatory compliance,” said Jeff Wendel, President and CEO of Chesapeake. “Adding Compass to the Chesapeake team expands our ability to serve clients who value efficient, quality-focused IRB reviews.”

“We are excited to join a respected, growing industry leader like Chesapeake. Their superior cloud-based IRB platform, CIRBI, will enable us to easily integrate our operations,” said Matt Baker, President and founder of Compass IRB.

Chesapeake IRB is a portfolio company of Linden Capital Partners.

About Chesapeake IRB

Chesapeake IRB has been providing independent IRB services for major pharmaceutical companies, biotech and medical device companies, universities, individual researchers, academic medical centers, and hospital systems since 1993. Chesapeake IRB earned AAHRPP accreditation in 2004 and was accredited for a fourth time in June 2015.

Chesapeake IRB offers a unique 21 CFR Part 11 compliant, electronic IRB platform (“CIRBI”), which is a fully transparent, paperless, and cloud-based IRB management platform on which all IRB submissions and management tasks are performed, documented, and available for audit purposes, 24/7.  CIRBI enables its staff to better serve its research partners with prompt reviews, resulting in faster subject enrollments.  For more information, please visit

About Linden Capital Partners

Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare and life sciences industries. Linden’s strategy is based upon three elements: i) healthcare and life science industry specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit